Trastuzumab Rechallenge in HER2-Positive Metastatic Breast Cancer: A Promising Strategy for Enhanced Progression-Free Survival Post Ado-Trastuzumab Emtansine Progression

Trastuzumab Rechallenge in HER2-Positive Metastatic Breast Cancer: A Promising Strategy for Enhanced Progression-Free Survival Post Ado-Trastuzumab Emtansine Progression

<i>Background and Objectives</i>: Metastatic breast cancer (MBC), particularly the HER2-positive subtype, represents a significant clinical challenge, with approximately 20–25% of breast cancer cases demonstrating HER2 overexpression. Trastuzumab, a monoclonal antibody targeting HER2, ha...

Full description

Saved in:
Bibliographic Details
Main Authors: Yunus Emre Altıntaş, Oğuzcan Kınıkoğlu, Anıl Yıldız, Deniz Işık, Uğur Özkerim, Sıla Öksüz, Tuğba Başoğlu Tüylü, Heves Sürmeli, Nedim Turan, Hatice Odabaş
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Medicina
Subjects:
HER2-positive breast cancer
trastuzumab re-challenge
lapatinib capecitabine
Online Access:https://www.mdpi.com/1648-9144/60/12/2069
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1648-9144/60/12/2069

Similar Items